CA2949932C - Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations - Google Patents

Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations Download PDF

Info

Publication number
CA2949932C
CA2949932C CA2949932A CA2949932A CA2949932C CA 2949932 C CA2949932 C CA 2949932C CA 2949932 A CA2949932 A CA 2949932A CA 2949932 A CA2949932 A CA 2949932A CA 2949932 C CA2949932 C CA 2949932C
Authority
CA
Canada
Prior art keywords
salt
disease
lymphoma
tgr
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2949932A
Other languages
English (en)
French (fr)
Other versions
CA2949932A1 (en
Inventor
Swaroop Kumar Venkata Satya VAKKALANKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhizen Pharmaceuticals AG
Original Assignee
Rhizen Pharmaceuticals AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals AG filed Critical Rhizen Pharmaceuticals AG
Publication of CA2949932A1 publication Critical patent/CA2949932A1/en
Application granted granted Critical
Publication of CA2949932C publication Critical patent/CA2949932C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2949932A 2014-05-27 2015-05-26 Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations Active CA2949932C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN2597CH2014 2014-05-27
IN2597/CHE/2014 2014-05-27
IN2596/CHE/2014 2014-05-27
IN2596CH2014 2014-05-27
PCT/IB2015/053940 WO2015181728A1 (en) 2014-05-27 2015-05-26 Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations

Publications (2)

Publication Number Publication Date
CA2949932A1 CA2949932A1 (en) 2015-12-03
CA2949932C true CA2949932C (en) 2021-08-10

Family

ID=53499042

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2949932A Active CA2949932C (en) 2014-05-27 2015-05-26 Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations

Country Status (22)

Country Link
US (4) US9969740B2 (https=)
EP (2) EP3971188A1 (https=)
JP (3) JP6987501B2 (https=)
KR (1) KR20170007480A (https=)
CN (2) CN106661030B (https=)
AU (1) AU2015265542B2 (https=)
BR (1) BR112016027674A2 (https=)
CA (1) CA2949932C (https=)
CY (1) CY1124316T1 (https=)
DK (1) DK3149000T3 (https=)
EA (1) EA032506B1 (https=)
ES (1) ES2880999T3 (https=)
HR (1) HRP20211151T1 (https=)
HU (1) HUE054916T2 (https=)
IL (1) IL249058B2 (https=)
LT (1) LT3149000T (https=)
PL (1) PL3149000T3 (https=)
PT (1) PT3149000T (https=)
RS (1) RS62136B1 (https=)
SI (1) SI3149000T1 (https=)
SM (1) SMT202100532T1 (https=)
WO (1) WO2015181728A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2880999T3 (es) * 2014-05-27 2021-11-26 Rhizen Pharmaceuticals S A Sal de tosilato cristalina de un inhibidor selectivo de PI3K delta para uso en formulaciones farmacéuticas
AU2017268839A1 (en) 2016-05-27 2018-11-29 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat B-cell proliferative disorders
CN110191720A (zh) 2016-09-09 2019-08-30 Tg治疗有限公司 用于治疗血液学癌症的抗-CD20抗体、PI 3激酶-δ抑制剂以及抗-PD-1或抗-PD-L1抗体的组合
JP2022540466A (ja) 2019-07-15 2022-09-15 ジョンソン、マッセイ、パブリック、リミテッド、カンパニー 非晶質ウムブラリシブモノトシレート
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2788383T3 (es) 2000-04-25 2020-10-21 Icos Corp Inhibidores de delta fosfatidilo-inositol 3-quinasa humana
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
CN102271683B (zh) 2008-11-13 2014-07-09 吉里德卡利斯托加公司 恶性血液病的治疗
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
CN102458410A (zh) 2009-04-20 2012-05-16 吉联亚·卡利斯托加有限责任公司 治疗实体瘤的方法
CN109970742A (zh) * 2012-07-04 2019-07-05 理森制药股份公司 选择性PI3Kδ抑制剂
ES2880999T3 (es) * 2014-05-27 2021-11-26 Rhizen Pharmaceuticals S A Sal de tosilato cristalina de un inhibidor selectivo de PI3K delta para uso en formulaciones farmacéuticas

Also Published As

Publication number Publication date
JP2017516785A (ja) 2017-06-22
IL249058B2 (en) 2023-03-01
JP6987501B2 (ja) 2022-01-05
JP2020122022A (ja) 2020-08-13
CN111635406A (zh) 2020-09-08
US10414773B2 (en) 2019-09-17
ES2880999T3 (es) 2021-11-26
EP3149000A1 (en) 2017-04-05
IL249058B (en) 2022-11-01
PT3149000T (pt) 2021-07-27
EA201692255A1 (ru) 2017-04-28
RS62136B1 (sr) 2021-08-31
SMT202100532T1 (it) 2021-11-12
US9969740B2 (en) 2018-05-15
HUE054916T2 (hu) 2021-10-28
LT3149000T (lt) 2021-09-10
CY1124316T1 (el) 2022-07-22
DK3149000T3 (da) 2021-08-30
BR112016027674A2 (pt) 2017-08-15
EP3149000B1 (en) 2021-06-30
US10947244B2 (en) 2021-03-16
US20190016725A1 (en) 2019-01-17
US20210269446A1 (en) 2021-09-02
CA2949932A1 (en) 2015-12-03
WO2015181728A1 (en) 2015-12-03
US20170121336A1 (en) 2017-05-04
CN106661030A (zh) 2017-05-10
AU2015265542B2 (en) 2019-05-09
HRP20211151T1 (hr) 2021-10-15
US20190382411A1 (en) 2019-12-19
AU2015265542A1 (en) 2016-12-08
KR20170007480A (ko) 2017-01-18
JP2022082680A (ja) 2022-06-02
EP3971188A1 (en) 2022-03-23
IL249058A0 (en) 2017-01-31
CN106661030B (zh) 2020-06-30
EA032506B1 (ru) 2019-06-28
PL3149000T3 (pl) 2021-11-02
SI3149000T1 (sl) 2021-09-30

Similar Documents

Publication Publication Date Title
US10414773B2 (en) Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations
AU2017227929B2 (en) Dosage form compositions comprising an inhibitor of Bruton's tyrosine kinase
EP3153170B1 (en) Methods and uses of the quinoline derivative anlotinib in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same
CN103764149A (zh) 新型替卡格雷共晶
JP2024533423A (ja) 薬学的組成物およびその使用
CN109988104B (zh) 山奈酚与异烟酰胺共晶物及制备方法和其药物组合物与用途
CN106659761A (zh) 初级癌症疗法后使用的含硼蛋白酶体抑制剂
CN118574622B (zh) Senaparib和替莫唑胺的复方制剂及其制备方法
HK1236026B (en) Crystalline tosylate salt of a pi3k delta selective inhibitor for use in pharmaceutical formulations
CN115124420B (zh) 大黄酸与苦参碱共晶物水合物及制备方法和其组合物与用途
CN101155600B (zh) 放射线治疗增强剂
WO2019008426A1 (en) NOVEL ENZALUTAMIDE ORAL GALENIC FORM COMPOSITION AND METHOD OF MANUFACTURING THE SAME
CA3218977A1 (en) A plurality of tasquinimod particles and use thereof
EA042667B1 (ru) Улучшенные формы селективного ингибитора pi3k-дельта для применения в фармацевтических препаратах
KR20230026415A (ko) 경구 제제 및 이의 용도
HK40110967A (zh) 药物组合物及其用途
WO2019130194A1 (en) Novel drug products of picropodophyllin
HK1118704B (en) Radiotherapy enhancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200507

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251224

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260318

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260407